Nikolai Kley

This inventor holds 34 USPTO granted patents and 28 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Chimeric Proteins. Top assignees: Orionis Biosciences Bv, Orionis Biosciences, Inc., Vib Vzw. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nikolai Kley. Retrieved from https://idiyas.com/inventor/nikolai-kley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 28)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 32)

EPO Patents = 6 (Patent Applications = 39)

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 37(Granted Patents)

Location History:

Newton, MA (US) (2021 - 2023)
Waltham, MA (US) (2022 - 2024)

Company Filing History:

25 out of 25

Orionis Biosciences Bv

patents

17 out of 17

Orionis Biosciences, Inc.

Orionis Biosciences Nv

where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...

Areas of Expertise:

Chimeric Proteins

Interferon Alpha

Binding Agents

CD8 Binding

Fibroblast Activation

PD-1

PD-L1

Clec9A

Mutant Interferons

Combination Therapy

Therapeutic Targeting

Bi-functional Agents

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758640 - Bifunctional agents for protein recruitment and/or degradation (2026-10-13),

2. 12753233 - Methods of cancer treatment with PD-L1 targeted interferon therapeutic agents (2026-10-06),

3. 12752000 - IMMUNOSTIMULATORY ADJUVANTS (2026-10-06),

4. 12655186 - CHIMERIC PROTEIN COMPRISING ANTI-XCR1 ANTIBODY AND MODIFIED INTERFERON ALPHA 2 (2026-06-16),

5. 12583941 - Fibroblast activation protein binding agents and use thereof (2026-03-24),

6. 12583898 - THERAPEUTIC INTERFERON ALPHA 1 PROTEINS (2026-03-24),

7. 12576127 - FIBROBLAST BINDING AGENTS AND USE THEREOF (2026-03-17),

8. 12546776 - Modulation of protein degradation (2026-02-10),

9. 12544426 - COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXES (2026-02-10),

10. 12522641 - Targeted mutant interferon-gamma and uses thereof (2026-01-13),

11. 12497436 - CHIMERIC PROTEIN, AND ENCODING NUCLEIC ACID THEREOF, COMPRISING INTERFERON-BETA AND A TARGETING MOIETY COMPRISING A SINGLE-DOMAIN ANTIBODY OR SINGLE-CHAIN ANTIBODY (2025-12-16),

12. 12473338 - TARGETED ENGINEERED INTERFERON AND USES THEREOF (2025-11-18),

13. 12453770 - CLEC9A binding agents (2025-10-28),

14. 12448447 - CD8 binding agents (2025-10-21),

15. 12410225 - Modulation of dendritic cell lineages (2025-09-09),

Title: Nikolai Kley: Pioneering Inventor from Newton, MA

Introduction: Nikolai Kley is a renowned inventor based in Newton, MA, known for his groundbreaking contributions to various fields of technology and innovation.

Latest Patents: Nikolai Kley holds several patents in the areas of renewable energy, artificial intelligence, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: With a career spanning over two decades, Nikolai Kley has worked with leading research institutions and companies to develop cutting-edge technologies that have revolutionized the industry.

Collaborations: Throughout his career, Nikolai Kley has collaborated with top universities, research institutions, and multinational corporations to bring his inventions to life, fostering a culture of innovation and progress.

Conclusion: Nikolai Kley's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a trailblazing inventor in the field of technology, inspiring future generations to push the boundaries of what is possible.

Profile summary based on public USPTO records.